Data supporting the structural and functional characterization of Thrombin‐Activatable Fibrinolysis Inhibitor in breast cancer  by Fawzy, Manal S. & Toraih, Eman A.
Contents lists available at ScienceDirect
Data in Brief





E-mjournal homepage: www.elsevier.com/locate/dibData articleData supporting the structural and functional
characterization of Thrombin‐Activatable
Fibrinolysis Inhibitor in breast cancerManal S. Fawzy a, Eman A. Toraih b,n
a Department of Medical Biochemistry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
b Department of Histology and Cell Biology (Genetics Unit), Faculty of Medicine, Suez Canal University,
Ismailia, Egypta r t i c l e i n f o
Article history:
Received 23 September 2015
Accepted 19 October 2015
Available online 14 November 2015x.doi.org/10.1016/j.dib.2015.10.043
09/& 2015 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author. Tel.: þ20 1008550681.
ail address: emantoraih@gmail.com (E.A. Toa b s t r a c t
The data in this paper is related to the research article entitled
“Thrombin-activatable ﬁbrinolysis inhibitor Thr325Ile poly-
morphism and plasma level in breast cancer: A pilot study” (Fawzy
et al., 2015) [1]. Many emerging studies have begun to unravel the
pathophysiologic role of the ﬁbrinolytic system in breast cancer
(BC) progression (Zorio et al., 2008) [2]. Activation of the ﬁbrino-
lytic plasminogen/plasmin system results in degradation of protein
barriers, thereby mediating cell migration essential for tumor
growth, angiogenesis, and dissemination (Castellino and Ploplis,
2005) [3]. In the current study, in silico data analysis of Thrombin-
Activatable Fibrinolysis Inhibitor (TAFI) gene and protein has been
done. Data have been retrieved from several databases mentioned
in details in the text. Determination and analysis of the structural
and functional impact of TAFI and its expression could help elu-
cidate the contribution of the TAFI pathway to acquired hemostatic
dysfunction and will form the basis of potential therapeutic stra-
tegies to manipulate this pathway. An inhibition of TAFI (e.g. by FXI
inhibitors) will offer the therapeutic possibilities to improve the
decreased ﬁbrinolysis and increase the efﬁciency of ﬁbrinolytic
therapy in thrombotic disorders including cancer.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.mgene.2015.03.004
raih).
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Value of the data
 This data provides a comprehensive in silico analysis of the structural and functional character-
ization of TAFI and its expression.
 The data are useful for understanding the effect of TAFI variants on its structure and function.
 This data may provide insight for determining the role of future drug treatment to inhibit TAFI
function especially in cancer cases.1. Data, experimental design, materials and methods
1.1. TAFI activation and function
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) represents the molecular link between the
coagulation and ﬁbrinolytic pathways [4,5] (Fig. 1). Human TAFI, also known as carboxypeptidase
basic (CPB2) and unstable (CPU), is a procarboxypeptidase enzyme and a member of the family of
metallocarboxypeptidases that carries a zinc ion essential for catalytic action and preferentially
cleaves the carboxyl-terminal peptide bonds of basic amino acids [6,7]. TAFI protein is encoded by
TAFI gene at 13q14.11 spanning about 58 kb of genomic DNA. It has 2 different transcripts of 1717 and
1655 base pairs due to alternative splicing (Fig. 2). TAFI protein is synthesized by the liver as a single
chain glycoprotein zymogen with a molecular weight of 60.0 kDa, circulates in the plasma in an
inactive form bound to plasminogen [8–9]. TAFI protein has 3 main domains; signal peptide of 22
residues, activation peptide (propeptide domain) of 92 amino acids, and catalytic chain of 309 resi-
dues (Fig. 3). Crystal structure of TAFI revealed that the precursor protein, in the zymogen form, exists
as a globular domain followed by an extended alpha-helix. It maintains its stability via the interaction
of the activation peptide with a highly dynamic region from residues 318–372 in the catalytic domain
[10]. Dissociation of the activation peptide increases the dynamic ﬂap mobility of this 55 residue
segment and consequently results in increased plasticity of the entire catalytic chain, complete
unfolding, and exposure of the cryptic thrombin-cleavage site present at Arg324 [11] (Fig. 4).
TAFI activity is generated during the blood clotting process via binding to thrombin, thrombin–
thrombomodulin complex, or plasmin, which in turn cleave TAFI protein at Arg114 (residue Arg92
after removal of the signal peptide) into N-terminal activation peptide and catalytic domains, leading
to exposure of the active site cleft of activated TAFI (TAFIa) [10,13]. The rate of thrombin catalyzed
activation of TAFI is increased by 1250 fold by formation of a ternary complex with thrombomodulin
(T-TM-TAFI) rather than the binary thrombin–TAFI complex (T–TAFI) [14]. TAFIa exhibits
Fig. 1. Coagulation and ﬁbrinolytic cascades. Ca, calcium; FDPs, ﬁbrin degradation product; PAI-1 and PAI-2; plasminogen
activator inhibitors; PL, phospjolipids; TAFI, thrombin activatable ﬁbrinolysis inhibitor; TF, tissue factor; tPA, tissue plasmi-
nogen activator; uPA, urokinase plasminogen activator. Both intrinsic and extrinsic pathways involved with a series of
sequential cleavage events which ends with thrombin activation from its zymogen prothrombin. Active thrombin can then
catalyze the polymerization of ﬁbrin monomers which converts soluble ﬁbrinogen into an insoluble ﬁbrin matrix. As the clot
forms, circulating red blood cells, white blood cells, and platelets become incorporated into its structure. In addition, ﬁbrin
becomes cross-linked providing further structural stability. On the other hand, ﬁbrinolysis, through the action of plasmin,
prevents unnecessary accumulation of intravascular ﬁbrin and enables the removal of thrombi. Plasmin is generated from the
zymogen plasminogen on the surface of the ﬁbrin clot by either tissue plasminogen activator (tPA) or urokinase (uPA) [3].
Proteolysis of ﬁbrin gives rise to soluble ﬁbrin degradation products (FDPs), some of which have immunomodulatory and
chemotactic functions [2]. The coagulation and ﬁbrinolytic systems are highly regulated and interrelated through mechanisms
that insure balanced hemostasis. The molecular linker between the two processes, TAFI, is ﬁrst produced as a proenzyme that is
activated by thrombin or plasmin generated during the coagulation cascade. The active form, TAFIa, inhibits ﬁbrinolysis by
cleaving off C-terminal lysine residues from partially degraded ﬁbrin. These residues act as a template onto which both tPA and
plasminogen bind thereby enhancing the catalytic efﬁciency of plasmin formation. Cleavage of these basic amino acids down-
regulates ﬁbrinolysis.
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are essential for binding and activation of plasminogen. Consequently, removal of these residues leads
to less plasmin formation and subsequently down-regulates ﬁbrinolysis and stabilizing the clots [15].
TAFI is unique among carboxypeptidases in that the TAFIa decays spontaneously into the inactive
form of TAFI (TAFIai) through a temperature-dependent conformational change, thus attaining a short
half-life, a property that is crucial for its role in controlling blood clot lysis [10,16]. In addition to the
role of TAFI in ﬁbrinolysis regulation, TAFIa also plays a role in the modulation of inﬂammation
through down-regulation of pericellular plasminogen activation and inactivation of the inﬂammatory
peptides bradykinin and anaphylatoxins C3a and C5a [16]. Other biological functions of TAFI were
elucidated; including cell migration, blood pressure and tissue repair [4] (Fig. 5).
Fig. 2. Genomic structure of the TAFI gene. (A) TAFI gene location. The TAFI gene (MIM 603101) is located in chromosome
13q14.11. The complete gene spans 58.190 kb of genomic DNA (NC_000013.11: Chr 13:46053186 to 46105076, complement
strand; human genome assembly GRCh38.p2: Annotation release 107). LCP1, lymphocyte cytosolic protein 1 (L-plastin);
LOC105370191 and LOC105370192, uncharacterized ncRNA; ZC3H13, zinc ﬁnger CCCH-type containing 13. (B) Splice variants of
TAFI gene. The ENSG00000080618 gene (RefSeq gene ID 1361) has 2 transcripts due to alternative splicing. CPB2-001 tran-
script: Coding exons: 11, Transcript length: 1717 bp, Translation length: 423 residues (Q96IY4). CPB2-201 transcript: Coding
exons: 10, Transcript length: 1655 bp, Translation length: 386 residues (A0A087WSY5-1). Transcript alignment between the
two splice variants revealed extra 50 bases at 50UTR, extra 1 base at 30UTR, and lack of exon 7 of 111 bases in the CPB2-201
transcript (Data source: Ensembl.org and UniProtKB).
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The plasma concentration of TAFI appears to be under the control of genetic factors and non-
genetic factors [16]. Several diseases, including diabetes, kidney transplantation, hypertension,
nephritic syndrome, insulin resistance, obesity, and inﬂammatory bowel disease, have been shown to
be positively associated with plasma TAFI levels [17]. In cancer, Expression Atlas databases reported
over-expression of TAFI levels in breast, ovarian, and hepatic cancer cell lines [18,19]. Plasma levels of
TAFI were found to be signiﬁcantly increased in various types of cancer; including BC [1,20], lung
cancer [21], gastric carcinoma [22], and multiple myeloma [23]. In addition, higher TAFI levels were
associated with a more advanced cancer stage [1,23]. The mechanism of increased circulating levels of
Fig. 3. Amino acids sequence of TAFI protein isoforms. (A) Q96IY4-1 isoform. That is the main protein encoded by the gene;
other forms are denoted as artifact (according to Vega Genome Browser release 62-Aug 2015 © WTSI / EBI and Consensus CDS
protein set release 18). Letters highlighted green for signal peptide (22 residues: 1–22); maroon for activation peptide (92
residues: 23–114); clear color for main protein chain with catalytic activity (309 residues: 115–423). Zinc ﬁnger pocket (2
histidines and one glutamate), cleavage site by thrombin, and active site (catalytic residue: C-terminal glutamate) are indicated
in the ﬁgure. (B) Q96IY4-2 isoform. Same sequence as isoform 1 except have missing 37 amino acids equivalent for exon
7 sequence from 198 to 234 residues and sequence distal to 384 till the end of isoform 1 is replaced by another 14 amino acids
thus lacking the active site E385 essential for catalytic activity. (C) A0A087WSY5 protein share characteristics of Q96IY4-1 and
Q96IY4-2. It has an identical sequence to isoform 1 except amino acids of exon 7 which are missing as in isoform 2. (Data
source: UniProtKB for Q96IY4 and A0A087WSY5, last modiﬁed on July 22, 2015).
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cytokines induced by cancer cells may stimulate the production and secretion of TAFI from liver or
vascular endothelial cells and thus increase its circulatory levels. Besides, malignant cells may also be
Fig. 4. Secondary structure of TAFI protein. (A) Schematic representation of TAFI protein domains (UniProtKB Q96IY4-1). TAFI,
Thrombin activatable ﬁbrinolysis inhibitor; TAFIa, activated TAFI; TAFIai, inactive form. TAFI protein is a single chain glyco-
protein zymogen of 423 amino acids long and molecular weight of 48.4 kDa that reach 60.0 kDa after glycosylation. It consists
of three main domains; signal peptide (22 amino acids long), N-terminal activation peptide (92 amino acids), and a catalytic
domain (309 amino acids), with a single molecule of zinc ion. Secondary structure features (helix, turn, and strand segments)
are indicated (Data source: Ensembl and UniProtKB). (B) Graphical representation of the topology of TAFI generated with
ProtterServer. It is a non-membranous protein secreted into the extracellular space. Red residues; 22 amino acids of the signal
peptide. Green squares; N-glycosylation (PTMs; post-transcriptional modiﬁcations) 4 located at residues 44, 73, 85, and 108 of
the activation peptide, and one in the catalytic domain at residue 241. Carbohydrates represent 19% of the protein components.
Disulphide bonds between 178 and 191, 250 and 274, 265 and 279. The cofactor zinc coordination site (H181, E184, H310) and
the basic C-terminal amino acid substrate binding pocket (S321, G358, D371) are indicated. Red arrow; site of proteolytic
cleavage at Arg92–Ala93 bond by thrombin or plasmin, which results in the dissociation of the activated peptide (92 amino
acids) from catalytic domain (309 amino acids) and exposure of the active site (Annotation data sources: UniProtKB, Phobius
predictions, PeptideAtlas database) [12].
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Fig. 5. Functional activity of TAFI. (A) Gene ontology (GO) of human TAFI. The extracellular TAFI protein participates in multiple
cellular processes [Data from: NextProt beta (http://www.nextprot.org) and GeneCards human gene database (http://www.
genecards.org/) and MGI annotation for mammalian phenotype browser (http://www.informatics.jax.org/)]. (B) Subcellular
localization of TAFI protein in the extracellular space. The conﬁdence of the evidence is color coded, ranging from light green
for low conﬁdence to dark green for higher conﬁdence. White indicates an absence of localization evidence (Data source:
Compartment web server based on manually curated literature, high-throughput screens, automatic text mining, and
sequence-based prediction methods: compartments.jensenlab.org/). (C) The STRING network view of TAFI protein. The net-
work nodes are proteins. Predicted functional links between the proteins are indicated by edges. Modes of action are shown in
different colored lines. A blue line indicates binding interaction; a grey line with green arrow shows proteins which activate
TAFI protein; black edge states for reaction evidence. The string global score (conﬁdence score) was adjusted to be greater than
0.95. CPE, carboxypeptidase E; CPN1, carboxypeptidase N, polypeptide 1; CPN2, carboxypeptidase N, polypeptide 2; F2, coa-
gulation factor II (thrombin); INS, insulin; PLG, plasminogen; PPARA, peroxisome proliferator-activated receptor alpha; Ligand-
activated transcription factor; PROC, protein C (inactivator of coagulation factors Va and VIIIa); PSMA6, proteasome (prosome,
macropain) subunit, alpha type, 6; UBE2A, ubiquitin-conjugating enzyme E2A (http://string.embl.de/).
M.S. Fawzy, E.A. Toraih / Data in Brief 5 (2015) 981–989 987
Fig. 6. Genetic variants of TAFI gene. (A) Distribution of variants in TAFI gene. The types of coding polymorphisms are shown in
the pie chart (Data source: human assembly GRCh38.p2 Annotation release 107; Ensembl.org). (B) Common variants in TAFI
protein. TAFI gene contains 2 common variants rs3742264 and rs1926447 at positions 46073959 and 46055809 with MAF of
0.31 (T) and 0.22 (A), respectively. Predicted functional impact of A169T and T347I using PolyPhen server demonstrated them to
be benign with a score of 0.00 (sensitivity: 1.0; speciﬁcity: 0.0) (Data source: dbSNP release 142).
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tumoral ﬁbrin deposition and thus promotes tumor cell growth and dissemination [24].1.3. Functional genetic variants of TAFI gene
According to several databases, TAFI gene contains multiple variants; all are rare with minor allele
frequencies (MAF) of less than 0.001 except two common natural variants rs3742264 and rs1926447
at positions 46073959 and 46055809 with MAF of 0.31 (T) and 0.22 (A), respectively, Fig. 6. Although
our in silico analysis predicted these two coding SNPs to be functionally neutral using polymorphism
phenotyping (PolyPhen) version 2 and MutPred web-based programs [25], however, evidences from
prior studies revealed that Thr169 and Thr347 are associated with higher plasma TAFI levels [5,26]
and that the 1040 T for C substitution results in a TAFIa species with a prolonged half-life at 37 °C [27].
Possibly, this increased stability of TAFIa compensates for the decreased levels of the protein [5].
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